Our work balances academic expertise with business achievement, and is driven by our belief that patients should benefit first from the genomic revolution.
Click on individual images to learn more.
As scientists at University of Cambridge, Jelena and Robert not only had access to cutting edge technology in genomics, but they could also meet patients affected by rare diseases and their families. It immediately became clear that technology developed in the last decade and commonly used in their day-to-day research was not yet helping most patients in the clinic.
GeneAdviser stemmed from their shared vision that patients should benefit first from the genomic revolution.